January 2017/Amala Cancer Research Centre/Mutation Research
Text/Wu Tingyao

Most people don’t think about Ganoderma lucidum until they get sick. They simply forget that Ganoderma lucidum can also be used for the preventive treatment of disease. According to a report published by the Amala Cancer Research Centre of India in the “Mutation Research” in January 2017, Ganoderma lucidum triterpenes, which can effectively inhibit the survival of cancer cells, can reduce the occurrence and severity of tumors, whether used externally or internally.
Ganoderma lucidum triterpenes make cancer cells not live well.
The study used the total triterpenoid extract of the fruiting body of Ganoderma lucidum. Researchers put it together with MCF-7 human breast cancer cells (estrogen-dependent) and found that the higher the concentration of the extract, the longer the time it takes to interact with cancer cells, the more it can reduce the survival rate of cancer cells, and even in some cases, it can make cancer cells disappear completely (as shown below).

(Figure remade by Wu Tingyao, data source / Mutat Res. 2017; 813: 45-51.)

Further analysis of the anti-cancer mechanism of Ganoderma lucidum total triterpenes revealed that after cancer cells are adjusted by Ganoderma lucidum triterpenes, many genes and protein molecules in the cells will undergo great changes. In detail, the originally active cyclin D1 and Bcl-2 and Bcl-xL will be suppressed while the originally quiet Bax and Caspase-9 will become restless.

Cyclin D1, Bcl-2 and Bcl-xL will promote the continuous proliferation of cancer cells while Bax and caspase-9 will initiate the apoptosis of cancer cells so that cancer cells can age and die like normal cells.

External use experiment: Ganoderma lucidum triterpenes prevent skin tumors.
Applying Ganoderma lucidum total triterpenes to animals can also exert a preventive inhibitory effect on tumors. The first is the induction experiment of “cutaneous papilloma” (Editor’s note: This is a benign papillary tumor that protrudes from the surface of the skin. If its base extends below the epidermis, it will easily deteriorate into skin cancer):

The carcinogen DMBA (dimethyl benz[ある]anthracene, a polycyclic aromatic hydrocarbon compound that can cause genetic mutations) was applied to the back of the experimental mouse (its hair had been shaved) to induce skin lesions.
後 1 week, the researchers applied croton oil, a substance that promotes tumor growth, to the same area twice a week, and also applied 5, 10, または 20 mg of Ganoderma lucidum triterpenes 40 minutes before each application of croton oil for 8 consecutive weeks (the 2nd to 9th week of the experiment).

After that, the researchers stopped applying harmful substances and Ganoderma lucidum but continued to raise the mice and observe their conditions. At the end of the 18th week of the experiment, the mice in the untreated control group, regardless of the incidence of tumors, the number of tumors that grew, and the time to grow the first tumor, were significantly different from the mice that were applied with 5, 10, そして 20 mg of Ganoderma lucidum triterpenes (下の図に示すように). (注記: 12 mice per group.)

The incidence of skin papilloma after 18 weeks of exposure to carcinogens
(Figure drawn by Wu Tingyao, data source / Mutat Res. 2017; 813: 45-51.)

The average number of tumors on the skin of each mouse after 18 weeks of exposure to carcinogens
(Figure drawn by Wu Tingyao, data source / Mutat Res. 2017; 813: 45-51.)

The time it takes to grow a tumor after exposure to carcinogens
(Figure drawn by Wu Tingyao, data source / Mutat Res. 2017; 813: 45-51.)
Feeding experiment: Ganoderma lucidum triterpenes prevent breast cancer.
The second is the “breast cancer” experiment: mice were fed carcinogen DMBA once a week for 3 weeks, and from the next day after the first carcinogen feeding (24 hours later), 10, 50 または 100 mg/kg of Ganoderma lucidum triterpenes were fed every day for 5 consecutive weeks.
The results are almost the same as the previous skin papilloma experiments. The control group without any treatment has a 100% chance of developing breast cancer. Ganoderma lucidum triterpenes can significantly reduce the incidence of tumors; the mice that ate Ganoderma lucidum were significantly different from the mice that didn’t eat Ganoderma lucidum in the number of tumors that grew and the time to grow the first tumor (下の図に示すように).
The tumor weights of mice protected with 10, 50 または 100 mg/kg total extract of Ganoderma lucidum triterpenes were only two-thirds, one-half and one-third of the tumor weights of mice in the control group, respectively.

Incidence of breast cancer
(Figure drawn by Wu Tingyao, data source / Mutat Res. 2017; 813: 45-51.)

The average number of tumors on the skin of each mouse at the 17th week after eating carcinogens
(Figure drawn by Wu Tingyao, data source / Mutat Res. 2017; 813: 45-51.)

The time it takes for mice to grow tumors after eating carcinogens
(Figure drawn by Wu Tingyao, data source / Mutat Res. 2017; 813: 45-51.)

Ganoderma lucidum triterpenes have both safe and effective advantages.

The results of the above two animal experiments clearly tell us that whether oral administration or external application of Ganoderma lucidum total triterpenes can effectively reduce the incidence of tumors, reduce the number of tumors and delay the appearance of tumors.

The mechanism of Ganoderma lucidum total triterpenes may be related to the regulation of genes and protein molecules in tumor cells mentioned earlier in this article. The research team has previously confirmed that Ganoderma lucidum total triterpenes do not harm normal cells, showing that Ganoderma lucidum total triterpenes are both safe and effective.

In this modern society full of health crises, it is a fantasy to avoid carcinogens. How to ask for blessings in troubled times? Products containing Ganoderma lucidum total triterpenes may be your ideal sustenance.

[ソース] Smina TP, 他. Ganoderma lucidum total triterpenes induce apoptosis in MCF-7 cells and attenuate DMBA induced mammary and skin carcinomas in experimental animals. Mutat Res. 2017; 813: 45-51.
著者について/Mさん. 呉廷耀

ウー・ティンヤオ氏は、以来、霊芝に関する直接の情報を報告し続けている。 1999. 彼女は『霊芝によるヒーリング』の著者です(4月に人民医学出版社に出版 2017).

★この記事は著者の独占的な許可を得て掲載されています.

★上記作品は転載禁止です, 著者の許可なく抜粋または他の方法で使用される.

★ For violations of the above statement, the author will pursue relevant legal responsibilities.

★この記事の原文はWu Tingyaoが中国語で執筆し、Alfred Liuが英語に翻訳しました。. 翻訳に齟齬があった場合 (英語) そしてオリジナル (中国語), 本来の中国人が勝つだろう. 読者に質問がある場合, 原作者に連絡してください, MS. 呉廷耀.